New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
08:08 EDTMNTAMomenta Pharma stills sees 2013 operating cash use about $90M
Momenta confirmed its guidance, previously provided in November, for total operating expenses, excluding stock-based compensation and net of collaborative revenues, of approximately $30M per quarter in 2013. For 2013, Momenta is projecting that its net cash usage will average approximately $20M-$24M per quarter for a total operating cash usage of approximately $90M.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTMNTAOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
08:48 EDTMNTAMomenta downgraded to Sell with $7 price target at Maxim
Maxim downgraded Momenta Pharmaceuticals two notches to Sell from Buy and cut its price target for shares to $7 from $17. The firm lowered its revenue assumptions for Copaxone after the Supreme Court sent the patent suit back to the Court of Appeals Federal Circuit.
07:23 EDTMNTAMomenta downgraded to Sell from Buy at Maxim
January 22, 2015
11:52 EDTMNTAMomenta sell-off provides good entry point, says Brean Capital
Subscribe for More Information
January 21, 2015
08:38 EDTMNTAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
January 20, 2015
10:40 EDTMNTAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use